<p>Retatrutide, a triple agonist developed by Eli Lilly, is showing promise in clinical trials for treating obesity and type 2 diabetes by targeting GLP-1, GIP, and glucagon receptors—resulting in notable weight loss and improved glucose control. With once-weekly dosing and fewer side effects, it offers a more manageable option for patients. According to Wikipedia, its triple hormone mechanism could outperform current medications like semaglutide and tirzepatide. As healthcare increasingly leverages personalized treatment strategies, lifestyle factors like nutrition and daily routines gain importance. Even tech-driven consumer platforms, such as those tracking Starbucks-menus, reflect how food choices can align with evolving health goals</p>